Structure Therapeutics Inc. (GPCR), a clinical-stage biopharmaceutical company focused on chronic metabolic and cardiopulmonary conditions, announced Friday positive results from Phase 1b clinical study of oral GLP-1 receptor agonist GSBR-1290 in healthy overweight or obese individuals.
Structure Therapeutics announced that clinical and preclinical data from its oral GLP-1 receptor agonist GSBR-1290 program will be presented at the upcoming American Diabetes Association (ADA) 83rd Scientific Sessions